CTOs on the Move

Catamaran Bio

www.catamaranbio.com

 
Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWINDTM Platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Catamaran Bio raised $42M on 11/23/2020

Similar Companies

TrovaGene

Trovagene is a molecular diagnostics company providing precise, noninvasive urine and blood testing for detecting and monitoring oncogene mutations. By utilizing proprietary technology that analyzes circulating tumor DNA, Trovagene testing offers critical data that may help inform cancer treatment decisions, giving physicians and patients monitoring options beyond biopsy or imaging.

Apple Valley Chamber-commerce

Apple Valley Chamber-commerce is a Apple Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regulus Therapeutics

Regulus is focused on the discovery and development of microRNA therapeutics. microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome.  A single microRNA can target and regulate up to hundreds of genes, and these genes are involved in biological networks or pathways.  Dysregulated microRNA expression is involved in the initiation of many complex multi-factoral diseases, including cancer, inflammatory disease, fibrosis, and metabolic disease. microRNA therapeutics are oligonucleotide medicines that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat  human disease. Regulus was formed in September 2007 by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS).  Regulus benefits substantially from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. Regulus has access to over 900 patents and patent applications pertaining to oligonucleotide technologies useful for targeting microRNA therapeutics, and over 170 patents and patent applications directed to microRNA specific technologies. Regulus is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery and drug development. Regulus’ scientific advisory board consists of world-class scientists and several of the foremost authorities in the field of microRNA research.  

Delaware BioScience Association

Delaware BioScience Association has a broad-based membership including pharmaceutical, biotechnology, medical devices, analytical equipment and agricultural products; as well as representatives from academia, medical research, workforce training and other supporting organizations (financial, legal, marketing, consulting, engineering and construction, etc.) that serve the bioscience community. Delaware Bio is focused on being a unified voice for Delaware and the region`s bioscience community to accelerate the growth of human, animal, plant, and industrial biosciences.

MOMA Therapeutics

We`re on a mission to unlock molecular machines by understanding and respecting their complexities. We`ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines.